195 related articles for article (PubMed ID: 35499381)
1. GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior.
Samms RJ; Cosgrove R; Snider BM; Furber EC; Droz BA; Briere DA; Dunbar J; Dogra M; Alsina-Fernandez J; Borner T; De Jonghe BC; Hayes MR; Coskun T; Sloop KW; Emmerson PJ; Ai M
Diabetes; 2022 Jul; 71(7):1410-1423. PubMed ID: 35499381
[TBL] [Abstract][Full Text] [Related]
2. GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models.
Borner T; Geisler CE; Fortin SM; Cosgrove R; Alsina-Fernandez J; Dogra M; Doebley S; Sanchez-Navarro MJ; Leon RM; Gaisinsky J; White A; Bamezai A; Ghidewon MY; Grill HJ; Crist RC; Reiner BC; Ai M; Samms RJ; De Jonghe BC; Hayes MR
Diabetes; 2021 Nov; 70(11):2545-2553. PubMed ID: 34380697
[TBL] [Abstract][Full Text] [Related]
3. Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding.
Adriaenssens A; Broichhagen J; de Bray A; Ast J; Hasib A; Jones B; Tomas A; Burgos NF; Woodward O; Lewis J; O'Flaherty E; El K; Cui C; Harada N; Inagaki N; Campbell J; Brierley D; Hodson DJ; Samms R; Gribble F; Reimann F
JCI Insight; 2023 May; 8(10):. PubMed ID: 37212283
[TBL] [Abstract][Full Text] [Related]
4. Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism.
Killion EA; Chen M; Falsey JR; Sivits G; Hager T; Atangan L; Helmering J; Lee J; Li H; Wu B; Cheng Y; Véniant MM; Lloyd DJ
Nat Commun; 2020 Oct; 11(1):4981. PubMed ID: 33020469
[TBL] [Abstract][Full Text] [Related]
5. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Zhang Q; Delessa CT; Augustin R; Bakhti M; Colldén G; Drucker DJ; Feuchtinger A; Caceres CG; Grandl G; Harger A; Herzig S; Hofmann S; Holleman CL; Jastroch M; Keipert S; Kleinert M; Knerr PJ; Kulaj K; Legutko B; Lickert H; Liu X; Luippold G; Lutter D; Malogajski E; Medina MT; Mowery SA; Blutke A; Perez-Tilve D; Salinno C; Sehrer L; DiMarchi RD; Tschöp MH; Stemmer K; Finan B; Wolfrum C; Müller TD
Cell Metab; 2021 Apr; 33(4):833-844.e5. PubMed ID: 33571454
[TBL] [Abstract][Full Text] [Related]
6. GIP receptor agonism blocks chemotherapy-induced nausea and vomiting.
Borner T; Reiner BC; Crist RC; Furst CD; Doebley SA; Halas JG; Ai M; Samms RJ; De Jonghe BC; Hayes MR
Mol Metab; 2023 Jul; 73():101743. PubMed ID: 37245848
[TBL] [Abstract][Full Text] [Related]
7. Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.
van Eenige R; Ying Z; Tramper N; Wiebing V; Siraj Z; de Boer JF; Lambooij JM; Guigas B; Qu H; Coskun T; Boon MR; Rensen PCN; Kooijman S
Atherosclerosis; 2023 May; 372():19-31. PubMed ID: 37015151
[TBL] [Abstract][Full Text] [Related]
8. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.
Irwin N; Hunter K; Flatt PR
Peptides; 2007 Nov; 28(11):2192-8. PubMed ID: 17884253
[TBL] [Abstract][Full Text] [Related]
10. Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Adriaenssens AE; Biggs EK; Darwish T; Tadross J; Sukthankar T; Girish M; Polex-Wolf J; Lam BY; Zvetkova I; Pan W; Chiarugi D; Yeo GSH; Blouet C; Gribble FM; Reimann F
Cell Metab; 2019 Nov; 30(5):987-996.e6. PubMed ID: 31447324
[TBL] [Abstract][Full Text] [Related]
11. Short communication: Expression of transcripts for proglucagon, glucose-dependent insulinotropic peptide, peptide YY, and their cognate receptors, in feline peripheral tissues.
Zapata RC; McMillan C; Tong J; Chelikani PK
Res Vet Sci; 2019 Jun; 124():223-227. PubMed ID: 30928654
[TBL] [Abstract][Full Text] [Related]
12. Glucose-dependent insulinotropic polypeptide receptor systems in the hypothalamus and the brainstem regulate feeding and weight through distinct pathways.
Yada T
J Diabetes Investig; 2024 Mar; 15(3):282-284. PubMed ID: 38140849
[TBL] [Abstract][Full Text] [Related]
13. Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist.
Grunddal KV; Diep TA; Petersen N; Tough IR; Skov LJ; Liu L; Buijink JA; Mende F; Jin C; Jepsen SL; Sørensen LME; Achiam MP; Strandby RB; Bach A; Hartmann B; Frimurer TM; Hjorth SA; Bouvier M; Cox H; Holst B
Mol Metab; 2021 Jul; 49():101207. PubMed ID: 33711555
[TBL] [Abstract][Full Text] [Related]
14. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Killion EA; Wang J; Yie J; Shi SD; Bates D; Min X; Komorowski R; Hager T; Deng L; Atangan L; Lu SC; Kurzeja RJM; Sivits G; Lin J; Chen Q; Wang Z; Thibault SA; Abbott CM; Meng T; Clavette B; Murawsky CM; Foltz IN; Rottman JB; Hale C; Véniant MM; Lloyd DJ
Sci Transl Med; 2018 Dec; 10(472):. PubMed ID: 30567927
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
16. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.
Costa A; Ai M; Nunn N; Culotta I; Hunter J; Boudjadja MB; Valencia-Torres L; Aviello G; Hodson DJ; Snider BM; Coskun T; Emmerson PJ; Luckman SM; D'Agostino G
Mol Metab; 2022 Jan; 55():101407. PubMed ID: 34844019
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular biology of the GIP receptor.
Greenwell AA; Chahade JJ; Ussher JR
Peptides; 2020 Mar; 125():170228. PubMed ID: 31812593
[TBL] [Abstract][Full Text] [Related]
18. GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice.
Furber EC; Hyatt K; Collins K; Yu X; Droz BA; Holland A; Friedrich JL; Wojnicki S; Konkol DL; O'Farrell LS; Baker HE; Coskun T; Scherer PE; Kusminski CM; Christe ME; Sloop KW; Samms RJ
Diabetes; 2024 Feb; 73(2):292-305. PubMed ID: 37934926
[TBL] [Abstract][Full Text] [Related]
19. Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Killion EA; Lu SC; Fort M; Yamada Y; Véniant MM; Lloyd DJ
Endocr Rev; 2020 Jan; 41(1):. PubMed ID: 31511854
[TBL] [Abstract][Full Text] [Related]
20. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
Samms RJ; Christe ME; Collins KA; Pirro V; Droz BA; Holland AK; Friedrich JL; Wojnicki S; Konkol DL; Cosgrove R; Furber EPC; Ruan X; O'Farrell LS; Long AM; Dogra M; Willency JA; Lin Y; Ding L; Cheng CC; Cabrera O; Briere DA; Alsina-Fernandez J; Gimeno RE; Moyers JS; Coskun T; Coghlan MP; Sloop KW; Roell WC
J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 34003802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
